INCY - Incyte Corporation
78.51 0.00 (0.00%)
After hours: 5:21PM EDT
| Previous close | 78.59 |
| Open | 78.76 |
| Bid | 78.46 x 1000 |
| Ask | 78.51 x 900 |
| Day's range | 78.36 - 80.37 |
| 52-week range | 57.00 - 89.30 |
| Volume | 575,695 |
| Avg. volume | 1,126,415 |
| Market cap | 16.885B |
| Beta (3Y monthly) | 0.93 |
| PE ratio (TTM) | 55.25 |
| EPS (TTM) | 1.42 |
| Earnings date | 29 Oct 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 93.59 |
- Zacks
What's in the Cards for Sarepta (SRPT) This Earnings Season?
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
- Business Wire
Incyte to Present at Upcoming Investor Conference
Incyte Corporation announced today that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am / 10:35 am in Scottsdale, Arizona.
- Zacks
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?
AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
- Zacks
Nokia (NOK) to Report Q3 Earnings: What's in the Offing?
Solid progress in its expansion areas of Software and Enterprise and excellent momentum in IP Routing business are likely to have benefited Nokia's (NOK) third-quarter 2019 financial results.
- Zacks
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
- Zacks
Editas Inks Deal for Gene Editing Neurological Disease Drugs
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
- Zacks
Novavax Begins Phase III Study on Influenza Vaccine Candidate
Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
- Business Wire
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Incyte Corporation (INCY) today announced positive results from the Novartis-sponsored pivotal Phase 3 REACH2 study evaluating ruxolitinib (Jakafi®) in patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint of improving overall response rate (ORR) at Day 28 with ruxolitinib treatment compared to best available therapy.
- Zacks
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
- Zacks
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance
The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.
- Simply Wall St.
Is Incyte Corporation's (NASDAQ:INCY) CEO Pay Justified?
Hervé Hoppenot became the CEO of Incyte Corporation (NASDAQ:INCY) in 2014. This report will, first, examine the CEO...
- Business Wire
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
- Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream
- Zacks
Seattle Genetics Begins Phase III Study on Tucatinib Combo
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
- Zacks
bluebird Inks Genome Editing Research Deal With Novo Nordisk
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
- Business Wire
Incyte to Report Third Quarter Financial Results
Incyte Corporation announced today that it has scheduled its third quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2019.
- Zacks
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
- Zacks
Incyte Sees Hammer Chart Pattern: Time to Buy?
Incyte has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
- Zacks
Merck's Pediatric Filings for Dificid Get FDA's Priority Review
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
- Zacks
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?
Is (INCY) Outperforming Other Medical Stocks This Year?
- Zacks
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
- Business Wire
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
WILMINGTON, Del.-- -- Data presented at ESMO support the planned submission of a New Drug Application to the U.S. Food and Drug Administration for pemigatinib before the end of 2019 Investor conference call and webcast scheduled for today, September 27, at 5:00 p.m. CEST Sixth paragraph, fourth sentence of release should read: Serous retinal detachment was observed in 4 percent of patients with none ...
- Zacks
Incyte Treats First Patient in Phase III Vitiligo Study
Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
- Business Wire
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Incyte (INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo. “Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group Vice President and Head of Inflammation and Autoimmunity Group, Incyte.
